The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.

ABSTRACT: In human gliomas, anti-tumor T cell responses are inhibited through induction of local and systemic immunosuppression. Immune checkpoint blockade is proving to be a success in several types of cancers. However, many studies reported that the treatment of glioblastoma patients with anti-CTLA-4 or anti-PD-1 has no survival benefit compared to standard chemotherapy. This study aimed to investigate the expression and role of VISTA, a newly described immune checkpoint regulator, in human gliomas. mRNA expression was assessed in a total of 87 samples from glioma patients. 57 glioma tissues were taken at different grades. 20 peripheral blood mononuclear cells (PBMC) samples were taken before surgery and ten after surgery, all from the same set of patients. As for the control, ten specimens of PBM

SUBMITTER: Ghouzlani A 

PROVIDER: S-EPMC8563991 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature